The global market is expected to enjoy a valuation of US$ 9.3 Billion by the end of the year 2023, and further expand at a CAGR of 12.1% to reach a valuation of US$ 29.1 Billion by the year 2033. According to the recent study by Future Market Insights, clinical data management systems (CDMS) are leading the market with an expected share of about 22.6% in the year 2023, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 8.4 Billion |
| Market Value 2023 | US$ 9.3 Billion |
| Market Value 2033 | US$ 29.1 Billion |
| CAGR 2023 to 2033 | 12.1% |
| Market Share of Top 5 Countries | 59.5% |
| Key Market Players List | Oracle, Datatrak International, Inc., Dassault Systemes, CRF Health, eClinicalWorks, Parexel International Corporation, Bioclinica, eClinical Solutions, IBM Watson Health, Anju Life Sciences Software, and ERT Clinical |
Increased funding for clinical research and the life sciences will help insure that eClinical solutions software is widely used, supporting the expansion of the eClinical solutions market. The market size for eClinical solutions and software is anticipated to soar as a result of biopharmaceutical and pharmaceutical businesses increasing their research and development efforts in line with the increased use of software solutions in clinical trials.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for eclinical solutions and software was around 2.9% of the overall ~US$ 286.4 Billion of the global digital health market in 2022.
The sale of eclinical solutions and software expanded at a CAGR of 10.6% from 2017 to 2022.
The COVID-19 epidemic has caused the market to change. The bulk of biotech and pharmaceutical businesses have focused their research and development efforts on helping to develop a COVID-19 vaccine. Numerous businesses have made large investments in analytics to combat COVID-19.
The pandemic caused some clinical trials to transition to a fully virtual/hybrid paradigm, which sharply increased demand for eClinical products and software.
The COVID-19 outbreak is anticipated to hasten the move toward digital workplace practices in the clinical trial industry while also bringing about long-term modifications to trial management norms. It might be a significant gain for all eClinical software firms if virtual and remote working modes show to be practical ways to conduct studies.
To address the specific needs of contemporary eClinical trial management, they will need a comprehensive eClinical works portal and trial platforms that adapt to evolving unmet needs. Thus, owing to the aforementioned factors, the global eclinical solutions and software market is expected to grow at a CAGR of 12.1% during the forecast period between 2023 and 2033.
| Market Statistics | Details |
|---|---|
| Jan - Jun (H1), 2021 (A) | 9.20% |
| Jul - Dec (H2), 2021 (A) | 11.88% |
| Jan - Jun (H1),2022 Projected (P) | 9.20% |
| Jan - Jun (H1),2022 Outlook (O) | 9.73% |
| Jul - Dec (H2), 2022 Outlook (O) | 12.08% |
| Jul - Dec (H2), 2022 Projected (P) | 11.45% |
| Jan - Jun (H1), 2023 Projected (P) | 9.81% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 53↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 52↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 63↑ |
| BPS Change: H2, 2022 (O) - H2, 2021 (A) | 20↑ |
Principal Consultant
The need for tracking and evaluating clinical data is anticipated to increase dramatically as the volume of data produced throughout clinical development processes rises. The size of the market for eClinical software and solutions in clinical trials grows as a result.
Clinical trial efficiency is increased, expenditures are decreased, and duplicated data entry is eliminated thanks to eClinical technologies. The aforementioned factors are expected to cause the market for eClinical solutions and software to expand.
The market forecast for eClinical solutions and software is anticipated to be positively impacted by the rapid adoption of tools like RTSM for patient enrollment and randomization as well as effective trial drug supply management.
The outsourcing of clinical trials to contract research organizations (CROs) and the growth of CROs and life sciences firms are both expected to drive the industry ahead in the future years. Growing research initiatives in Asian nations and the development of affordable modules are also fueling the expansion of the global market.
The high initial cost mixed with ongoing maintenance expenditures is one of the primary barriers to the market trends and forecasts for eClinical systems and software.
The cost of eClinical Works is anticipated to increase further if eClinical Works software is adopted, which requires a sizeable investment. Given that some sponsors are concentrating on conducting multi-site clinical trials concurrently, the price of eClinical services is anticipated to increase even more swiftly.
There are several challenges in the way of providing high-quality, cheap, and accessible healthcare in low- and middle-income nations. Increasing regulatory hurdles are made worse by increasing clinical trial complexity and data volumes, which will limit the demand for eClinical solutions and software in the coming years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Country | USA |
|---|---|
| Market Share 2023 | 36.7% |
| Market Share 2033 | 44.6% |
| BPS Analysis | 791 |
| Country | Germany |
|---|---|
| Market Share 2023 | 7.7% |
| Market Share 2033 | 8.7% |
| BPS Analysis | 95 |
| Country | United Kingdom |
|---|---|
| Market Share 2023 | 5.7% |
| Market Share 2033 | 9.2% |
| BPS Analysis | 349 |
| Country | China |
|---|---|
| Market Share 2023 | 4.6% |
| Market Share 2033 | 3.6% |
| BPS Analysis | -99 |
| Country | Canada |
|---|---|
| Market Share 2023 | 4.3% |
| Market Share 2033 | 3.9% |
| BPS Analysis | -32 |
The USA is set to hold a market share of about 39.3% in 2023, and is expected to continue to experience the same growth throughout the forecast period.
This is due to the expanding target population and rising rates of lifestyle-related disorders including diabetes and heart conditions, which are anticipated to drive future trends in the eClinical solutions and software industry.
The launch of new products by providers of eClinical solutions and a rise in government funds are further boosting the market in the nation.
Germany is set to hold a market share of nearly 7.3% in the global eclinical solutions and software market in 2022.
This is because of the existence of notable players and the accessibility of advanced infrastructure within the nation. The market for eClinical solutions is expanding because of a growing emphasis on research and development capabilities for medical devices and the adoption of advanced healthcare technology, as well as improved IT spending allocations for drug development and rising costs for the establishment of healthcare infrastructure.
China is set to expand at 8.7% CAGR over the forecast period.
The demand for eClinical solutions and software is being fueled by the significant unmet medical requirements in the nation as well as the increased prevalence of targeting chronic diseases including cancer, cardiovascular problems, and infectious diseases.
More studies are being outsourced to China because of the country's enormous patient population and inexpensive cost. Sales of eClinical software and solutions have peaked in China as a result of this outsourcing.
Government investment for research and drug development, which is a major driver of the region's growth as an emerging economy, is anticipated to bode well for key trends and prospects in the market for eClinical solutions and software.
Clinical data management systems (CDMS) are set to hold a share of around 22.6% in the global market, in 2023.
A technology used in clinical research to handle and maintain the data from a clinical trial is called a clinical data management system, or CDMS. Different techniques are employed by CDMS to evaluate clinical data and reduce errors brought on by human error during manual entry.
It is frequently integrated into current Clinical Trial Management Systems (CTMS) software; however, companies in the field more frequently sell these 2 components separately.
Web hosted (on-demand) solutions are set to hold a share of around 67.3% in the global market, in 2023.
The idea of on-demand services fits particularly well with cloud computing, which makes it simple and affordable to access server or virtual machine provision. The increased popularity for web-hosted solutions can be due to associated advantages including simplicity of use, usability, and far less financial outlay.
Phase III is set to hold a share of around 46.7% in the global market, in 2023.
Owed to the growing number of novel drug development activities, as well as the rising volumes of ongoing clinical trials, successful completion of initial assessment brings the drug product into the phase III of clinical trials. With a large number of such discoveries in their phase III of trials, this segment is under focus. Rising prevalence of diseases has propelled the growth of this segment.
Contract research organizations are set to hold a market share of around 35.8% in the global market in 2023.
Clinical trial outsourcing has gained momentum in recent years due to the contract research organizations’ (CROs) expansion of their areas of expertise. Clinical trial solutions that are effective, rapid, and dependable are now essential due to the demand for evolving medical technology and pharmaceutical treatments. Most of these trials take a lot of time, and they require medical knowledge to be successful.
The market is incredibly competitive and expanding as a result of rising technology adoption as well as smaller and mid-sized sponsors. The firm concentration ratio is anticipated to increase due to rising tendencies in the eClinical solutions and software industry in regions like Asia Pacific and South America, creating possibilities for smaller enterprises to expand.
Further, it has been shown that eClinical software businesses are pursuing a number of growth approaches, such as partnerships, acquisitions and mergers and development of new products, all of which are helping them to increase their market share.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the eclinical solutions and software space, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Solution, Delivery Mode, Clinical Trial, End User, and Region |
| Key Companies Covered |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is valued at US$ 9.3 billion in 2023.
Dassault Systemes, CRF Health, and eClinicalWorks are prominent market players.
The market is forecast to register a CAGR of 12.1% through 2033.
The market will reach US$ 29.1 billion by 2033.
From 2017 to 2022, the market registered a CAGR of 10.6%.
1. Executive Summary | eClinical Solutions and Software Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Market Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Technological Assessment
4.3. Regulatory Landscape
4.4. Reimbursement Scenario
4.5. Promotional Strategies, By Key Players
4.6. PESTEL Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Digital Health Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Growing Contract Research Activities
5.2.2. Demand for Efficient Clinical Trial Management Systems
5.2.3. Rising Drug Development Activities
5.2.4. Rise in Government Funding for Clinical Trials
5.2.5. Cost of Software Implementation and Upgrades
5.2.6. Growing Burden of Chronic and Infectious Diseases
5.2.7. Rising Volumes of Clinical Trial Studies
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Solution
6.1.2. By Delivery Mode
6.1.3. By Clinical Trial
6.1.4. By End User
6.1.5. By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2017 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Mn) Analysis, 2017 to 2022
7.2. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Solution
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Solution, 2017 to 2022
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Solution, 2023 to 2033
8.3.1. Randomization & Trial Management (RTSM)
8.3.2. Clinical Data Management System (CDSM)
8.3.3. Clinical Trial Management System (CLMS)
8.3.4. Electronic Clinical Outcome Assessment (eCOA)
8.3.5. Electronic Trial Master File (eTMF)
8.3.6. Electronic Data Capture
8.3.7. Others
8.4. Market Attractiveness Analysis By Solution
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Delivery Mode
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis, By Delivery Mode, 2017 to 2022
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Delivery Mode, 2023 to 2033
9.3.1. Licensed Enterprise (On-premise) Solution
9.3.2. Cloud-based (SAAS) Solution
9.3.3. Web-hosted (on-demand) Solution
9.4. Market Attractiveness Analysis By Delivery Mode
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Clinical Trial
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis, By Clinical Trial, 2017 to 2022
10.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Clinical Trial, 2023 to 2033
10.3.1. Phase I
10.3.2. Phase II
10.3.3. Phase III
10.3.4. Phase IV
10.4. Market Attractiveness Analysis By Clinical Trial
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis, By End User, 2017 to 2022
11.3. Current and Future Market Size (US$ Mn) Analysis Forecast By End User, 2023 to 2033
11.3.1. Contract Research Organization
11.3.2. Medical Device Companies
11.3.3. Pharma/Biotech Companies
11.3.4. Hospitals & Clinics
11.3.5. Others
11.4. Market Attractiveness Analysis By End User
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2017 to 2022
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. The USA
13.3.1.2. Canada
13.3.2. By Solution
13.3.3. By Delivery Mode
13.3.4. By Clinical Trial
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Solution
13.4.3. By Delivery Mode
13.4.4. By Clinical Trial
13.4.5. By End User
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. USA Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Solution
13.8.1.2.2. By Delivery Mode
13.8.1.2.3. By Clinical Trial
13.8.1.2.4. By End User
13.8.2. Canada Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Solution
13.8.2.2.2. By Delivery Mode
13.8.2.2.3. By Clinical Trial
13.8.2.2.4. By End User
14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Solution
14.3.3. By Delivery Mode
14.3.4. By Clinical Trial
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Solution
14.4.3. By Delivery Mode
14.4.4. By Clinical Trial
14.4.5. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Mexico Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Solution
14.8.1.2.2. By Delivery Mode
14.8.1.2.3. By Clinical Trial
14.8.1.2.4. By End User
14.8.2. Brazil Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Solution
14.8.2.2.2. By Delivery Mode
14.8.2.2.3. By Clinical Trial
14.8.2.2.4. By End User
14.8.3. Argentina Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Solution
14.8.3.2.2. By Delivery Mode
14.8.3.2.3. By Clinical Trial
14.8.3.2.4. By End User
15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. United Kingdom (UK)
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Solution
15.3.3. By Delivery Mode
15.3.4. By Clinical Trial
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Solution
15.4.3. By Delivery Mode
15.4.4. By Clinical Trial
15.4.5. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Solution
15.8.1.2.2. By Delivery Mode
15.8.1.2.3. By Clinical Trial
15.8.1.2.4. By End User
15.8.2. Italy Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Solution
15.8.2.2.2. By Delivery Mode
15.8.2.2.3. By Clinical Trial
15.8.2.2.4. By End User
15.8.3. France Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Solution
15.8.3.2.2. By Delivery Mode
15.8.3.2.3. By Clinical Trial
15.8.3.2.4. By End User
15.8.4. United Kingdom Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Solution
15.8.4.2.2. By Delivery Mode
15.8.4.2.3. By Clinical Trial
15.8.4.2.4. By End User
15.8.5. Spain Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Solution
15.8.5.2.2. By Delivery Mode
15.8.5.2.3. By Clinical Trial
15.8.5.2.4. By End User
15.8.6. BENELUX Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Solution
15.8.6.2.2. By Delivery Mode
15.8.6.2.3. By Clinical Trial
15.8.6.2.4. By End User
15.8.7. Russia Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Solution
15.8.7.2.2. By Delivery Mode
15.8.7.2.3. By Clinical Trial
15.8.7.2.4. By End User
16. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Solution
16.3.3. By Delivery Mode
16.3.4. By Clinical Trial
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Solution
16.4.3. By Delivery Mode
16.4.4. By Clinical Trial
16.4.5. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. China Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Solution
16.8.1.2.2. By Delivery Mode
16.8.1.2.3. By Clinical Trial
16.8.1.2.4. By End User
16.8.2. Japan Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Solution
16.8.2.2.2. By Delivery Mode
16.8.2.2.3. By Clinical Trial
16.8.2.2.4. By End User
16.8.3. South Korea Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Solution
16.8.3.2.2. By Delivery Mode
16.8.3.2.3. By Clinical Trial
16.8.3.2.4. By End User
17. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Solution
17.3.3. By Delivery Mode
17.3.4. By Clinical Trial
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Solution
17.4.3. By Delivery Mode
17.4.4. By Clinical Trial
17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. India Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Solution
17.8.1.2.2. By Delivery Mode
17.8.1.2.3. By Clinical Trial
17.8.1.2.4. By End User
17.8.2. Indonesia Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Solution
17.8.2.2.2. By Delivery Mode
17.8.2.2.3. By Clinical Trial
17.8.2.2.4. By End User
17.8.3. Malaysia Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Solution
17.8.3.2.2. By Delivery Mode
17.8.3.2.3. By Clinical Trial
17.8.3.2.4. By End User
17.8.4. Thailand Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Solution
17.8.4.2.2. By Delivery Mode
17.8.4.2.3. By Clinical Trial
17.8.4.2.4. By End User
18. Oceania Market 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Solution
18.3.3. By Delivery Mode
18.3.4. By Clinical Trial
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Solution
18.4.3. By Delivery Mode
18.4.4. By Clinical Trial
18.4.5. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Solution
18.8.1.2.2. By Delivery Mode
18.8.1.2.3. By Clinical Trial
18.8.1.2.4. By End User
18.8.2. New Zealand Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Solution
18.8.2.2.2. By Delivery Mode
18.8.2.2.3. By Clinical Trial
18.8.2.2.4. By End User
19. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. North Africa
19.3.1.4. South Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Solution
19.3.3. By Delivery Mode
19.3.4. By Clinical Trial
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Solution
19.4.3. By Delivery Mode
19.4.4. By Clinical Trial
19.4.5. By End User
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Solution
19.8.1.2.2. By Delivery Mode
19.8.1.2.3. By Clinical Trial
19.8.1.2.4. By End User
19.8.2. Türkiye Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Solution
19.8.2.2.2. By Delivery Mode
19.8.2.2.3. By Clinical Trial
19.8.2.2.4. By End User
19.8.3. South Africa Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Solution
19.8.3.2.2. By Delivery Mode
19.8.3.2.3. By Clinical Trial
19.8.3.2.4. By End User
19.8.4. North Africa Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Solution
19.8.4.2.2. By Delivery Mode
19.8.4.2.3. By Clinical Trial
19.8.4.2.4. By End User
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Concentration
20.4. Market Presence Analysis
20.4.1. By Regional Footprint of Players
20.4.2. Product Footprint of Players
20.4.3. Channel Footprint of Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Deep Dive
21.2.1. Oracle
21.2.1.1. Overview
21.2.1.2. Product Portfolio
21.2.1.3. Sales Footprint
21.2.1.4. Key Financials
21.2.1.5. SWOT Analysis
21.2.1.6. Strategy Overview
21.2.1.6.1. Marketing Strategy
21.2.1.6.2. Product Strategy
21.2.1.6.3. Channel Strategy
21.2.2. Datatrak International, Inc.
21.2.2.1. Overview
21.2.2.2. Product Portfolio
21.2.2.3. Sales Footprint
21.2.2.4. Key Financials
21.2.2.5. SWOT Analysis
21.2.2.6. Strategy Overview
21.2.2.6.1. Marketing Strategy
21.2.2.6.2. Product Strategy
21.2.2.6.3. Channel Strategy
21.2.3. Dassault Systemes
21.2.3.1. Overview
21.2.3.2. Product Portfolio
21.2.3.3. Sales Footprint
21.2.3.4. Key Financials
21.2.3.5. SWOT Analysis
21.2.3.6. Strategy Overview
21.2.3.6.1. Marketing Strategy
21.2.3.6.2. Product Strategy
21.2.3.6.3. Channel Strategy
21.2.4. CRF Health
21.2.4.1. Overview
21.2.4.2. Product Portfolio
21.2.4.3. Sales Footprint
21.2.4.4. Key Financials
21.2.4.5. SWOT Analysis
21.2.4.6. Strategy Overview
21.2.4.6.1. Marketing Strategy
21.2.4.6.2. Product Strategy
21.2.4.6.3. Channel Strategy
21.2.5. eClinicalWorks
21.2.5.1. Overview
21.2.5.2. Product Portfolio
21.2.5.3. Sales Footprint
21.2.5.4. Key Financials
21.2.5.5. SWOT Analysis
21.2.5.6. Strategy Overview
21.2.5.6.1. Marketing Strategy
21.2.5.6.2. Product Strategy
21.2.5.6.3. Channel Strategy
21.2.6. Parexel International Corporation
21.2.6.1. Overview
21.2.6.2. Product Portfolio
21.2.6.3. Sales Footprint
21.2.6.4. Key Financials
21.2.6.5. SWOT Analysis
21.2.6.6. Strategy Overview
21.2.6.6.1. Marketing Strategy
21.2.6.6.2. Product Strategy
21.2.6.6.3. Channel Strategy
21.2.7. Bioclinica
21.2.7.1. Overview
21.2.7.2. Product Portfolio
21.2.7.3. Sales Footprint
21.2.7.4. Key Financials
21.2.7.5. SWOT Analysis
21.2.7.6. Strategy Overview
21.2.7.6.1. Marketing Strategy
21.2.7.6.2. Product Strategy
21.2.7.6.3. Channel Strategy
21.2.8. eClinical Solutions
21.2.8.1. Overview
21.2.8.2. Product Portfolio
21.2.8.3. Sales Footprint
21.2.8.4. Key Financials
21.2.8.5. SWOT Analysis
21.2.8.6. Strategy Overview
21.2.8.6.1. Marketing Strategy
21.2.8.6.2. Product Strategy
21.2.8.6.3. Channel Strategy
21.2.9. IBM Watson Health
21.2.9.1. Overview
21.2.9.2. Product Portfolio
21.2.9.3. Sales Footprint
21.2.9.4. Key Financials
21.2.9.5. SWOT Analysis
21.2.9.6. Strategy Overview
21.2.9.6.1. Marketing Strategy
21.2.9.6.2. Product Strategy
21.2.9.6.3. Channel Strategy
21.2.10. Anju Life Sciences Software
21.2.10.1. Overview
21.2.10.2. Product Portfolio
21.2.10.3. Sales Footprint
21.2.10.4. Key Financials
21.2.10.5. SWOT Analysis
21.2.10.6. Strategy Overview
21.2.10.6.1. Marketing Strategy
21.2.10.6.2. Product Strategy
21.2.10.6.3. Channel Strategy
21.2.11. ERT Clinical
21.2.11.1. Overview
21.2.11.2. Product Portfolio
21.2.11.3. Sales Footprint
21.2.11.4. Key Financials
21.2.11.5. SWOT Analysis
21.2.11.6. Strategy Overview
21.2.11.6.1. Marketing Strategy
21.2.11.6.2. Product Strategy
21.2.11.6.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology
Healthcare
June 2024
REP-GB-14775
250 pages
Explore Healthcare Insights
View Reports
eClinical Solutions and Software Market
